(Q46747375)

24 December 2017

title

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response (English)

1 reference

24 December 2017

0 references

0 references

Ristic S

1

1 reference

24 December 2017

Byiers S

series ordinal

2

1 reference

24 December 2017

Foley J

series ordinal

3

1 reference

24 December 2017

Holmes D

series ordinal

4

1 reference

24 December 2017

publication date

1 November 2005

1 reference

24 December 2017

Diabetes, Obesity and Metabolism

published in

1 reference

24 December 2017

volume

7

1 reference

24 December 2017

issue

6

1 reference

24 December 2017

page(s)

692-698

1 reference

24 December 2017

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00539.X

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00539.X

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00539.X

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2005.00539.X

10.1111/J.1463-1326.2005.00539.X

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

PubMed ID

16219012

1 reference

24 December 2017